The Atopic dermatitis drugs Market size was valued at USD 14.93 billion in 2024 and is expected to reach USD 29.43 billion by 2032, growing at a CAGR of 8.92% over the forecast period of 2025-2032.
To Get more information on Atopic dermatitis drugs Market - Request Free Sample Report
The atopic dermatitis drugs market is experiencing robust growth as a result of growing disease prevalence, particularly in children and adolescents, coupled with heightened awareness and diagnosis rates. The increase in demand for specific biologics such as Dupixent and the evolution of treatment options are redefining patient care. Increasing healthcare access and R&D investments are fueling innovation, which makes the market extremely dynamic and promising for future therapeutic advancements.
For Instance, according to NIH, globally, atopic dermatitis affects 20% of children and 2–8% of adults, most of whom have a family or personal history of atopic diseases. The point prevalence of AD is increasing on all continents and is slightly higher in females (0.6–24.3%) than in males (0.8–17.6%).
Atopic dermatitis (eczema) medications are experiencing accelerated innovation, with emerging systemic therapies such as IL-4 and IL-13 inhibitors and JAK inhibitors with encouraging results. Although topical therapies and wet dressings are still valuable, systemic treatments provide a more focused means of controlling moderate to severe disease. The WHO, NIH, and other entities are engaged in research and guideline development for the management of atopic dermatitis, propelling the market growth.
The U.S. Atopic Dermatitis Drugs Market was valued at USD 5.61 billion in 2024 and is expected to reach USD 10.78 billion by 2032, growing at a CAGR of 8.57% from 2025-2032. The U.S. is the leader in the North American region due to the high incidence of the disease, well-developed healthcare infrastructure, and robust R&D activities.
Drivers
Rising Prevalence of Atopic Dermatitis is driving the market growth
Atopic dermatitis (AD) is being increasingly identified as a worldwide public health issue owing to its rising incidence, particularly in children. It occurs in as many as 20% of children and a significant percentage of adults globally. Urbanization, environmental pollution, dietary patterns, and genetic susceptibility are among the factors contributing to this increase. With the increasing number of people being diagnosed with AD, the need for efficient drug treatments is on the rise, making it a major market growth driver.
For Instance, according to NCBI, Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects about 10% of adults and up to 20% of children in affluent nations. AD has the greatest burden of all dermatological conditions in disability-adjusted life-years and is 15th among all non-lethal diseases worldwide. AD is a heterogeneous disease, and the nature of its symptoms can vary in intensity and presentation depending on genetic and environmental determinants. Approximately 80% of all cases start in early childhood, and about 60% of these enter remission during adolescence. Although adult-onset AD does exist, it is not as prevalent as childhood-onset disease.
Strong R&D Investment for the atopic dermatitis market is propelling the atopic dermatitis drugs market growth.
Developments in the biomedical sciences and technology are promoting a paradigm shift in R&D for new drug development. With escalating drug development costs and fewer new chemical entities (NCEs), pharmaceutical firms are prioritizing R&D activity, with considerable focus on clinical trials to minimize failure rates. The Atopic Dermatitis (AD) drugs market is a mirror of this interest, with a strong pipeline of more than 150 products in different stages of development. Of them, 43% (66 drugs) are in non-clinical phases, 16% (25) in Phase I, 33% (51) in Phase II, and 7% (11) in Phase III trials. Biologics comprise 50.33% (77) of the pipeline and small molecules 49.67% (76), which indicates a balanced and aggressive search for new therapies in this category.
Restraint
The High Cost of Biologic Therapies is restraining the market growth.
Biologic medications like Dupixent (dupilumab) have drastically changed the therapeutic approach to treat moderate-to-severe atopic dermatitis (AD), particularly in those poor responders to first-line therapies. These treatments are extremely targeted and provide great benefits clinically by working on particular processes of inflammation. Because of the extensive biotechnology, their manufacture makes them much pricier compared to conventional medication.
By Class
The biologics segment led with a 39.08% atopic dermatitis drugs market share in 2024, with their high potency in targeting selective immune pathways engaged in moderate-to-severe conditions of the disease. Biologics like Dupixent (dupilumab) provide long-term comfort and enhanced quality of life to patients who respond poorly to standard treatments. Their capacity to dampen inflammation and disease severity with fewer side effects has fueled extensive uptake among health professionals and patients. Moreover, higher FDA approvals and rising awareness have also added fuel to their market leadership.
PDE4 Inhibitors are anticipated to experience the fastest growth in the forecast period as a result of their ease of use, particularly in topical dosage forms, and good safety profile. PDE4 Inhibitors provide a targeted anti-inflammatory action with limited systemic exposure, thus ideal for mild-to-moderate diseases and long-term treatment. Recent launches such as Zoryve and new indications for already approved therapies are improving accessibility and usage, hence speeding up market growth.
By Route of Administration
The topical segment held the dominating share in the market with 40.12% in 2024, as the first-line treatment for mild to moderate atopic dermatitis. Topical therapies, including corticosteroids and calcineurin inhibitors, are usually prescribed because of their convenience, cost-effectiveness, and ability to provide localized pain relief with minimal systemic effect.
The parenteral segment will grow at the fastest rate during the forecast years with a CAGR of 9.53%, propelled primarily by increased use of biologics to treat moderate and severe atopic dermatitis. Injectable medicines like dupilumab deliver specific, prolonged control of the disease in topical treatment-resistant patients. Biologic form innovation, mounting awareness, and additional FDA approval are driving acceptance of parenteral therapy, primarily in the industrialized world.
By End Use
The hospital pharmacies segment dominated the atopic dermatitis drugs market with a 62.31% market share in 2024, based on greater dependency on hospital-based treatment for moderate to severe AD cases. Hospitals tend to act as the first line of treatment for patients with specialist referrals and biologic drugs, which tend to be prescribed under medical guidance.
The other pharmacies segment is expected to grow at the fastest rate over the forecast period, spurred by the growing trend towards telemedicine, home care, and outpatient procedures. Online drug stores and retail pharmacy chains are increasingly convenient and convenient for patients suffering from mild to moderate AD. These sites are also offered at competitive prices with home delivery and easy refills, which are making them an extremely popular option among consumers for the long-term treatment of atopic dermatitis.
The atopic dermatitis drugs market was led by North America in 2024 with a 46.20% market share due to its high disease prevalence, well-established medical infrastructure, strong presence of global pharmaceutical companies, and favorable reimbursement policies. The U.S. is a strong contributor with extensive use of newer therapies supported by strong R&D efforts. The trend of increasing biologic approvals and availability of sites for clinical trials also favor the leadership.
In July and June 2024, Dermavant's Vtama was approved in Japan, and Arcutis's Zoryve was approved in the US. Both have novel mechanisms of action (MoAs). Vtama, an agonist of the AhR receptor, represents a new way of treating atopic dermatitis (AD), which is different from other available therapies. Zoryve, a phosphodiesterase-4 (PDE4) inhibitor, has a similar MoA to Pfizer's Eucrisa (crisaborole). With these new approvals, the community of patients with AD looks forward to favorable results from both drugs in the patient population with AD.
Asia Pacific is the region with the fastest growth, with 9.59% CAGR over the forecast period, propelled by a huge patient base, rising healthcare expenditure, growing awareness, and rising access to sophisticated dermatological care in nations such as China and India. Efforts by the government to enhance the management of skin diseases and increased interest among international pharma players are driving quick market growth.
Germany is expected to lead the European market, followed by France, which is expected to be the fastest-growing region. Germany's leadership is attributed to its high awareness, positive reimbursement policies, and well-established healthcare infrastructure.
Latin America and the Middle East & and Africa are registering moderate growth due to improved healthcare infrastructure, rising awareness of skin diseases, and incremental access to advanced therapies. However, limited healthcare funding, declining rates of diagnosis, and restricted access to biologics are the moderating factors for faster market growth in these regions.
Get Customized Report as per Your Business Requirement - Enquiry Now
Sanofi, Regeneron Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., Eli Lilly and Company, LEO Pharma Inc., Novartis AG, Incyte Corporation, Bayer AG, Astellas Pharma Inc., and other players.
April 2025 Sanofi and Regeneron Pharmaceuticals, Inc., announced the U.S. Food and Drug Administration (FDA) has granted approval to Dupixent (dupilumab) for the treatment of adults aged 12 and older and adolescents with chronic spontaneous urticaria (CSU) who have an inadequate response to histamine-1 (H1) antihistamine therapy.
April 2025 AbbVie reported positive topline findings from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 trial that compared the efficacy and safety of upadacitinib (RINVOQ, 15 mg daily initial dose and dose-adjusted based on clinical response) with dupilumab (DUPIXENT, according to its labeled dose) in adult and adolescent (≥12 years of age) patients with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of such therapies was inadvisable.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 14.93 Billion |
| Market Size by 2032 | USD 29.43 Billion |
| CAGR | CAGR of 8.92% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others) • By Route of Administration (Topical, Parenteral, Oral) • By End Use (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Sanofi, Regeneron Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., Eli Lilly and Company, LEO Pharma Inc., Novartis AG, Incyte Corporation, Bayer AG, Astellas Pharma Inc., and other players. |
Ans: The Atopic Dermatitis Drugs Market is expected to grow at a CAGR of 5.60% from 2025-2032.
Ans: The Atopic Dermatitis Drugs Market was USD 63.60 billion in 2024 and is expected to reach USD 103.82 billion by 2032.
Ans: Rising Prevalence of Atopic Dermatitis is driving the market growth.
Ans: The “Topical” segment dominated the Atopic Dermatitis Drugs Market.
Ans: North America dominated the Atopic Dermatitis Drugs Market in 2024.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prevalence and Incidence of Atopic Dermatitis (2023)
5.2 Prescription Trends by Drug Class and Region (2023)
5.3 Healthcare Spending by Region (Government, Commercial, Private, Out-of-Pocket) – 2023
5.4 Biologics Penetration and Uptake (2020–2032)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Atopic Dermatitis Drugs Market Segmentation By Class
7.1 Chapter Overview
7.2 Atopic Dermatitis Drugs
7.2.1 Atopic Dermatitis Drugs Market Trends Analysis (2021-2032)
7.2.2 Atopic Dermatitis Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Calcineurin Inhibitors
7.3.1 Calcineurin Inhibitors Market Trends Analysis (2021-2032)
7.3.2 Calcineurin Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 PDE4 Inhibitors
7.4.1 PDE4 Inhibitors Market Trends Analysis (2021-2032)
7.4.2 PDE4 Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Biologics
7.5.1 Biologics Market Trends Analysis (2021-2032)
7.5.2 Biologics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2021-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Atopic Dermatitis Drugs Market Segmentation By Route of Administration
8.1 Chapter Overview
8.2 Topical
8.2.1 Topical Market Trend Analysis (2021-2032)
8.2.2 Topical Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Parenteral
8.3.1 Parenteral Market Trends Analysis (2021-2032)
8.3.2 Parenteral Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Oral
8.4.1 Oral Market Trends Analysis (2021-2032)
8.4.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Atopic Dermatitis Drugs Market Segmentation By End Use
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Other Pharmacies
9.4.1 Other Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Other Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.2.4 North America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.2.5 North America Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.2.6.2 USA Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.2.6.3 USA Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.2.7.2 Canada Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.2.7.3 Canada Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.2.8.2 Mexico Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.2.8.3 Mexico Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.4 Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.5 Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.6.2 Germany Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.6.3 Germany Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.7.2 France Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.7.3 France Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.8.2 UK Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.8.3 UK Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.9.2 Italy Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.9.3 Italy Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.10.2 Spain Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.10.3 Spain Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.11.2 Poland Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.11.3 Poland Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.12.2 Turkey Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.12.3 Turkey Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.4 Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.5 Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.6.2 China Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.6.3 China Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.7.2 India Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.7.3 India Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.8.2 Japan Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.8.3 Japan Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.9.2 South Korea Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.9.3 South Korea Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.10.2 Singapore Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.10.3 Singapore Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.11.2 Australia Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.11.3 Australia Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.5.6.2 UAE Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.5.6.3 UAE Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.5.8.2 Qatar Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.5.8.3 Qatar Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.5.9.2 South Africa Atopic Dermatitis Drugs Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
10.5.9.3 South Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.6.4 Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.6.5 Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.6.6.2 Brazil Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.6.6.3 Brazil Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.6.7.2 Argentina Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.6.7.3 Argentina Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Drug Class (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by Route of Administration (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Atopic Dermatitis Drugs Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
11. Company Profiles
11.1 Sanofi
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Regeneron Pharmaceuticals Inc.,
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 AbbVie Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Pfizer Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Eli Lilly and Company,
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 LEO Pharma Inc
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Novartis AG
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Incyte Corporation
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Bayer AG
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Astellas Pharma Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Class
Corticosteroids
Calcineurin Inhibitors
PDE4 Inhibitors
Biologics
Others
By Route of Administration
Topical
Parenteral
Oral
By End Use
Hospital Pharmacies
Retail Pharmacies
Other Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
Sickle cell disease treatment market size was valued at USD 3.23 billion in 2024 and is expected to reach USD 12.05 billion by 2032, growing at a CAGR of 17.93% over the forecast period 2025-2032.
Glaucoma Therapeutics Market was USD 8.85 billion in 2023 and is expected to Reach USD 14.71 billion by 2032 and grow at a CAGR of 5.83% from 2024 to 2032.
The Telerehabilitation Market Size was valued at USD 4.7 billion in 2023 and is expected to reach USD 15.4 billion by 2032 and grow at a CAGR of 14.1%.
The Multi-Cancer Early Detection Market was valued at USD 1.07 billion in 2023 and is expected to reach USD 4.40 billion by 2032, growing at a CAGR of 17.04% over the forecast period of 2024-2032.
The Laparoscopic Appendectomy Market was valued at USD 2.46 billion in 2023 and is expected to reach USD 3.83 billion by 2032, growing at a CAGR of 5.08% over the forecast period of 2024-2032.
The mRNA Technology Market was valued at USD 35.67 billion in 2023 and is expected to reach USD 76.45 billion by 2032 with a growing CAGR of 8.88%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
